1. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G.; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
Kidney Int 69:2006;1945–1953.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 76(Suppl 113):2009;S1–S130.
3. Moe S.M., Drueke T.. Improving global outcomes in mineral and bone disorders.
Clin J Am Soc Nephrol 3(Suppl 3):2008;S127–S130.
4. Isakova T., Wahl P., Vargas G.S., Gutiérrez O.M., Scialla J., Xie H., Appleby D., Nessel L., Bellovich K., Chen J., Hamm L., Gadegbeku C., Horwitz E., Townsend R.R., Anderson C.A., Lash J.P., Hsu C.Y., Leonard M.B., Wolf M.. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Kidney Int 79:2011;1370–1378.
6. Mian I.S.. Sequence, structural, functional, and phylogenetic analyses of three glycosidase families.
Blood Cells Mol Dis 24:1998;83–100.
7. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., Kuro-o M.. Regulation of fibroblast growth factor-23 signaling by klotho.
J Biol Chem 281:2006;6120–6123.
8. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T.. Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Nature 444:2006;770–774.
9. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., Quarles L.D.. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.
J Am Soc Nephrol 17:2006;1305–1315.
10. Chen C.D., Podvin S., Gillespie E., Leeman S.E., Abraham C.R.. Insulin stimulates the cleavage and release of the extracellular domain of klotho by ADAM10 and ADAM17.
Proc Natl Acad Sci USA 104:2007;19796–19801.
11. Hu M.C., Kuro-o M., Moe O.W.. Klotho and chronic kidney disease.
Contrib Nephrol 180:2013;47–63.
12. Hu M.C., Kuro-o M., Moe O.W.. Renal and extrarenal actions of klotho.
Semin Nephrol 33:2013;118–129.
13. Hu M.C., Shi M., Zhang J., Pastor J., Nakatani T., Lanske B., Razzaque M.S., Rosenblatt K.P., Baum M.G., Kuro-o M., Moe O.W.. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.
FASEB J 24:2010;3438–3450.
14. Cha S.K., Ortega B., Kurosu H., Rosenblatt K.P., Kuro-O M., Huang C.L.. Removal of sialic acid involving klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1.
Proc Natl Acad Sci USA 105:2008;9805–9810.
15. Kuro-o M.. Phosphate and klotho.
Kidney Int 79(Suppl 121):2011;S20–S23.
16. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y.. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med 351:2004;1296–1305.
17. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., Fujita T., Nakahara K., Fukumoto S., Yamashita T.. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
J Bone Miner Res 19:2004;429–435.
18. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W., Antman E.M., Smith S.C. Jr., Adams C.D., Anderson J.L., Faxon D.P., Fuster V., Halperin J.L., Hiratzka L.F., Jacobs A.K., Nishimura R., Ornato J.P., Page R.L., Riegel B.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.
Circulation 112:2005 e154–e235. Published online 2005 Sep 13. doi:
10.1161/CIRCULATIONAHA.105.167586.
19. Yamazaki Y., Imura A., Urakawa I., Shimada T., Murakami J., Aono Y., Hasegawa H., Yamashita T., Nakatani K., Saito Y., Okamoto N., Kurumatani N., Namba N., Kitaoka T., Ozono K., Sakai T., Hataya H., Ichikawa S., Imel E.A., Econs M.J., Nabeshima Y.. Establishment of sandwich ELISA for soluble alpha-klotho measurement: age-dependent change of soluble alpha-klotho levels in healthy subjects.
Biochem Biophys Res Commun 398:2010;513–518.
20. Imel E.A., Peacock M., Pitukcheewanont P., Heller H.J., Ward L.M., Shulman D., Kassem M., Rackoff P., Zimering M., Dalkin A., Drobny E., Colussi G., Shaker J.L., Hoogendoorn E.H., Hui S.L., Econs M.J.. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
J Clin Endocrinol Metab 91:2006;2055–2061.
21. European Best Practice Guidelines Expert Group on Hemodialysis; European Renal Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 17:2002;7–9.
22. Daugirdas J.T.. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error.
J Am Soc Nephrol 4:1993;1205–1213.
23. Devereux R.B., Reichek N.. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.
Circulation 55:1977;613–618.
24. Nakamura A., Shikata K., Hiramatsu M., Nakatou T., Kitamura T., Wada J., Itoshima T., Makino H.. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes.
Diabetes Care 28:2005;2890–2895.
25. Handa N., Matsumoto M., Maeda H., Hougaku H., Ogawa S., Fukunaga R., Yoneda S., Kimura K., Kamada T.. Ultrasonic evaluation of early carotid atherosclerosis.
Stroke 21:1990;1567–1572.
26. Shimamura Y., Hamada K., Inoue K., Ogata K., Ishihara M., Kagawa T., Inoue M., Fujimoto S., Ikebe M., Yuasa K., Yamanaka S., Sugiura T., Terada Y.. Serum levels of soluble secreted alpha-klotho are decreased in the early stages of CKD, making it a probable novel biomarker for early diagnosis.
Clin Exp Nephrol 16:2012;722–729.
27. Yokoyama K., Imura A., Ohkido I., Maruyama Y., Yamazaki Y., Hasegawa H., Urae J., Sekino H., Nabeshima Y., Hosoya T.. Serum soluble alpha-klotho in hemodialysis patients.
Clin Nephrol 77:2012;347–351.
28. Lindberg K., Amin R., Moe O.W., Hu M.C., Erben R.G., Östman Wernerson A., Lanske B., Olauson H., Larsson T.E.. The kidney is the principal organ mediating klotho effects.
J Am Soc Nephrol 25:2014;2169–2175.
29. Sawires H.K., Essam R.M., Morgan M.F., Mahmoud R.A.. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
Nephron 129:2015;293–299.
30. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., Sugimura K., Kishimoto T., Kinoshita S., Kuroki T., Nabeshima Y.. Severely reduced production of klotho in human chronic renal failure kidney.
Biochem Biophys Res Commun 280:2001;1015–1020.
31. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y.I.. Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
Nature 390:1997;45–51.
32. John G.B., Cheng C.Y., Kuro-o M.. Role of klotho in aging, phosphate metabolism, and CKD.
Am J Kidney Dis 58:2011;127–134.
33. Kitagawa M., Sugiyama H., Morinaga H., Inoue T., Takiue K., Ogawa A., Yamanari T., Kikumoto Y., Uchida H.A., Kitamura S., Maeshima Y., Nakamura K., Ito H., Makino H.. A decreased level of serum soluble klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.
PLoS One 8:2013 e56695.Published online 2013 Feb 19. doi:
10.1371/journal.pone.0056695.
34. Buiten M.S., de Bie M.K., Bouma-de Krijger A., van Dam B., Dekker F.W., Jukema J.W., Rabelink T.J., Rotmans J.I.. Soluble klotho is not independently associated with cardiovascular disease in a population of dialysis patients.
BMC Nephrol 15:2014;197.
35. Hu M.C., Shiizaki K., Kuro-o M., Moe O.W.. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.
Annu Rev Physiol 75:2013;503–533.
36. Semba R.D., Cappola A.R., Sun K., Bandinelli S., Dalal M., Crasto C., Guralnik J.M., Ferrucci L.. Plasma klotho and cardiovascular disease in adults.
J Am Geriatr Soc 59:2011;1596–1601.
37. Navarro-Gonzalez J.F., Donate-Correa J., Muros de Fuentes M., Perez-Hernandez H., Martinez-Sanz R., Mora-Fernandez C.. Reduced klotho is associated with the presence and severity of coronary artery disease.
Heart 100:2014;34–40.
38. Lim K., Lu T.S., Molostvov G., Lee C., Lam F.T., Zehnder D., Hsiao L.L.. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.
Circulation 125:2012;2243–2255.